JFJazmín Meneses Figueroa

Jazmín Meneses Figueroa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jazmín Meneses Figueroa has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital

    by Krista Yazareth Enríquez López, José Meneses Calderón, Lilia de la Cruz Ávila, Miguel Ángel López Esquivel, Jazmín Meneses Figueroa, María José Vargas Contreras, José Anaya Herrera, Ofelia Roxana Sotelo Martínez, José Antonio Mendoza López, Hugo Mendieta Zerón

    Nitazoxanide shows adequate in vitro activity against coronavirus. The aim of this study was to describe the behavior of coronavirus disease 2019 (COVID-19) in pregnant women treated with nitazoxanide. This cross-sectional study included the files of COVID-19 positive pregnant women treated with nitazoxanide 500 mg every 6 hours, levofloxacin every 12 hours, and clarithromycin 500 mg every 12 hours. The data of 51 women (mean age: 27.4 ± 7.2 years) were analyzed. Eleven (21.56%) patients had to receive medical attention in the intensive care unit. There were 22 (43.13%) preterm deliveries, 21 by cesarean and one by vaginal delivery. The medical attention of this population was as follows: 31 cesareans, five vaginal deliveries, nine still pregnant, two requiring manual vacuum aspiration, two ectopic pregnancies, one requiring curettage, and one requiring hysterotomy. There were seven (13.72%) cases of preeclampsia, and there were two (3.92%) deaths. Nitazoxanide prescription could be an option against COVID-19 in pregnancy due to its safety profile.


  • Open Access

    Nitazoxanide against COVID-19 in three explorative scenarios

    by José Meneses Calderón, Ma. del Rocío Figueroa Flores, Leopoldo Paniagua Coria, Jesús Carlos Briones Garduño, Jazmín Meneses Figueroa, María José Vargas Contretas, Lilia De la Cruz Ávila, Salvador Díaz Meza, Reynaldo Ramírez Chacón, Srivatsan Padmanabhan, et al.

    Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.